US-based brand-name and generic drugmaker ANI Pharmaceuticals (ANI) announced on 12 August 2015 that it had entered into a collaboration with generics company IDT Australia (IDT) to commercialize up to 18 previously marketed US generics.
ANI Pharma and IDT Australia collaborate on US generics
Home/Pharma News
|
Posted 28/08/2015
0
Post your comment

The news follows IDT’s announcement in April 2015 that the US Food and Drug Administration (FDA) had accepted the transfer of ownership of 23 generics to the Australia-based company [1].
ANI has paid US$1 million for the exclusive rights to commercialize the 18 generics in North America. ANI will also share in an undisclosed percentage of net profits upon commercialization. The total current annual US market for these products is estimated to be worth US$538 million, according to IMS Health.
IDT expects to file a CBE-30 (changes being effected) for the first generic drug product in the fourth quarter of 2015.
ANI has already acquired 53 generics from Teva Pharmaceuticals [2, 3]. This deal will further expand ANI’s generics portfolio.
Related article
Mergers between Watson/Actavis and ANI Pharma/BioSante
References
1. GaBI Online - Generics and Biosimilars Initiative. IDT Australia gets FDA nod for 23 generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/IDT-Australia-gets-FDA-nod-for-23-generics
2. GaBI Online - Generics and Biosimilars Initiative. ANI Pharmaceuticals acquires 22 generics from Teva [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/ANI-Pharmaceuticals-acquires-22-generics-from-Teva
3. GaBI Online - Generics and Biosimilars Initiative. ANI Pharmaceuticals acquires 31 generics from Teva [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/ANI-Pharmaceuticals-acquires-31-generics-from-Teva
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.
Source: ANI Pharma
Guidelines
Advances in EMA plans to streamline biosimilar assessment
FDA issues guidance on AI use in drug and biologicals regulatory decision making
Policies & Legislation
ANVISA and Danish Medicines Agency renew health regulatory collaboration
Colombia and Brazil introduce reforms to enhance healthcare regulation
Colombia boosts health sovereignty through public-private biotech collaboration agreement

Home/Pharma News Posted 07/04/2025
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment